Navigation Links
OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports

HONG KONG, Feb. 15 /PRNewswire/ -- OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is feasible and safe for use in acute myocardial infarction (AMI) patients, according to a paper published in the American Heart Journal (2008; Vol. 155, Issue 1: 128-132).

The paper, based on a study of 120 acute ST-elevation myocardial infarction (STEMI) patients who received a Genous stent, reports there was no incidence of late thrombosis and that the revascularization rate of 2.5% at six months is highly acceptable when compared to published primary percutaneous coronary intervention (PCI) rates for bare metal stents. The paper also highlighted the low rate of major adverse cardiac events (MACE): 4.2% at 30 days and 5.8% at six months.

Entitled "Use of endothelial progenitor cell capture stent (Genous Bio-engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate- to long-term clinical follow up," the paper was authored by Dr. Huay Cheem Tan. The study was conducted at National University Hospital and Tan Tock Seng Hospital in Singapore.

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit

Global Media Contact:

David Schull

Russo Partners LLC

+1 212-845-4271 (office)

+1 858-717-2310 (mobile)

SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
4. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
5. UPDATE: Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
6. Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
7. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
8. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
9. Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting
10. Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
11. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:11/30/2015)... , Dec. 1, 2015  An interventional radiology technique shows ... the preliminary results of a study being presented today at ... North America (RSNA). --> ... for decades by interventional radiologists as a way to stop ... procedure as a means of treating obesity is new. ...
(Date:11/30/2015)... /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today ... to its Board of Directors to replace Dr. ... wealth of experience as co-founder of Resverlogix, with expertise in ... --> --> Dr. Wong remarked, "I am ... Zenith,s long standing expertise in epigenetics and the advanced stage ...
(Date:11/30/2015)... Florida , November 30, 2015 ... specializing in the development of innovative peptide and gene-based ... metastatic disease, today announced it will be presenting at ... on December 1, 2015 at 2.30 PM PT. Dr. ... and Strategic Advisor will be giving the presentation and ...
(Date:11/30/2015)... , Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: ... DCVax® personalized immune therapies for solid tumor cancers, announced ... additional independent director, and the Company welcomes Neil ... in a recent anonymous internet report on NW Bio.  ... Linda Powers stated, "We agree with ...
Breaking Biology Technology:
(Date:11/19/2015)... 19, 2015  Based on its in-depth analysis of ... BIO-key with the 2015 Global Frost & Sullivan Award ... Sullivan presents this award to the company that has ... needs of the market it serves. The award recognizes ... expands on customer base demands, the overall impact it ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
Breaking Biology News(10 mins):